Periodontal disease is one of the most prevalent chronic conditions on the planet. According to the CDC, 47% of American adults over 30 have some form of periodontitis. Globally, severe periodontal disease affects more than one billion people.
Yet for all its prevalence, the treatment options remain remarkably limited.
The Clinical Reality
When periodontal disease progresses, it destroys the bone that supports your teeth. Once that bone is gone, it doesn't come back on its own. The tooth becomes loose. Eventually, it falls out or must be extracted.
Current treatments focus on halting disease progression—scaling and root planing, antibiotics, improved hygiene. But they don't restore lost bone. For that, patients need surgery: bone grafts, guided tissue regeneration, or complex reconstructive procedures.
These surgeries are expensive, invasive, and unpredictable. Outcomes vary widely based on the surgeon's skill, the patient's health, and the specific characteristics of the defect.
The Market Opportunity
The periodontal therapeutics market exceeds $30 billion annually. This includes:
- Professional treatments and procedures
- Prescription and OTC therapeutics
- Dental implants (often needed after tooth loss from periodontal disease)
Despite this massive market, there is no approved therapy that predictably regenerates periodontal bone without surgery.
Growth factors like PDGF have shown some efficacy but require surgical placement and have limitations in larger defects. BMP-based products face safety concerns. Grafting materials provide a scaffold but rely on the body's own (often limited) regenerative capacity.
The Unmet Need
What clinicians and patients need is a solution that:
- Regenerates bone predictably
- Can be applied without invasive surgery
- Works in the challenging oral environment
- Has a clean safety profile
This is precisely what Oral BioLife's piezoelectric platform is designed to deliver.
Ambrilux™ Dental Gel
Our lead product, Ambrilux™, is an injectable, light-curable scaffold that a periodontist can place directly into a bone defect during a routine office visit. No flap surgery. No general anesthesia. No extended recovery.
Once in place, the scaffold harnesses the patient's natural chewing forces to generate piezoelectric signals that activate bone formation.
Pre-clinical results have demonstrated 100% bone regeneration response—a result that, if replicated in humans, would represent a significant advance over current standards of care.
The Path Forward
We're advancing Ambrilux toward first-in-human studies in 2026, with U.S. commercial launch targeted for the second half of 2027. The regulatory pathway is De Novo—appropriate for a first-in-class device with a novel mechanism of action.
For the billion-plus people living with periodontal bone loss, a non-surgical regenerative option can't come soon enough.